Literature DB >> 19305965

Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes.

M L Marcovecchio1, R N Dalton, C P Schwarze, A T Prevost, H A W Neil, C L Acerini, T Barrett, J D Cooper, J Edge, J Shield, B Widmer, J A Todd, D B Dunger.   

Abstract

AIMS/HYPOTHESIS: The relationship between BP and microalbuminuria in young people with type 1 diabetes is not completely clear. As microalbuminuria is preceded by a gradual rise in albumin excretion within the normal range, we hypothesised that ambulatory BP (ABP) may be closely related to albumin excretion and progression to microalbuminuria.
METHODS: ABP monitoring (ABPM) was performed in 509 young people with type 1 diabetes (age median [range]: 15.7 [10.7-22.6] years) followed with annual assessments of three early morning urinary albumin:creatinine ratios (ACRs) and HbA(1c). Systolic BP (SBP) and diastolic BP (DBP) and the nocturnal fall in BP were analysed in relation to ACR.
RESULTS: All ABPM variables were significantly related to baseline log(10) ACR (p < 0.001). After the ABPM evaluation, 287 patients were followed for a median of 2.2 (1.0-5.5) years. ABP at baseline was independently related to mean ACR during follow-up. Nineteen initially normoalbuminuric patients developed microalbuminuria after 2.0 (0.2-4.0) years and their baseline daytime DBP was higher than in normoalbuminuric patients (p < 0.001). After adjusting for baseline ACR and HbA(1c), there was an 11% increased risk of microalbuminuria for each 1 mmHg increase in daytime DBP. Forty-eight per cent of patients were non-dippers for SBP and 60% for DBP; however, ACR was not different between dippers and non-dippers and there were no differences in the nocturnal fall in BP between normoalbuminuric and future microalbuminuric patients. CONCLUSIONS/
INTERPRETATION: In this cohort of young people with type 1 diabetes, ABP was significantly related to ACR, and daytime DBP was independently associated with progression to microalbuminuria. Increasing albumin excretion, even in the normal range, may be associated with parallel rises in BP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305965     DOI: 10.1007/s00125-009-1327-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  44 in total

Review 1.  Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society.

Authors:  E O'Brien; A Coats; P Owens; J Petrie; P L Padfield; W A Littler; M de Swiet; F Mee
Journal:  BMJ       Date:  2000-04-22

2.  Ambulatory blood pressure, microalbuminuria, and autonomic neuropathy in adolescents with type 1 diabetes.

Authors:  A R Lafferty; G A Werther; C F Clarke
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

3.  Clinical and research aspects of ambulatory blood pressure monitoring in children.

Authors:  Empar Lurbe; Jonathon M Sorof; Stephen R Daniels
Journal:  J Pediatr       Date:  2004-01       Impact factor: 4.406

4.  Ethnic and gender differences in ambulatory blood pressure trajectories: results from a 15-year longitudinal study in youth and young adults.

Authors:  Xiaoling Wang; Joseph C Poole; Frank A Treiber; Gregory A Harshfield; Coral D Hanevold; Harold Snieder
Journal:  Circulation       Date:  2006-11-27       Impact factor: 29.690

Review 5.  Ambulatory blood-pressure monitoring.

Authors:  Thomas G Pickering; Daichi Shimbo; Donald Haas
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

6.  Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients.

Authors:  S T Knudsen; E Laugesen; K W Hansen; T Bek; C E Mogensen; P L Poulsen
Journal:  Diabetologia       Date:  2009-01-29       Impact factor: 10.122

7.  Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus.

Authors:  P H Gallego; A J Gilbey; M T Grant; M K Bulsara; G C Byme; T W Jones; F L Frazer
Journal:  J Pediatr Endocrinol Metab       Date:  2005-09       Impact factor: 1.634

8.  Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.

Authors:  Rachel M Williams; Kevin Yuen; Debbie White; Beth Mallard; R Neil Dalton; Carlo L Acerini; David B Dunger
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

9.  The LMS method for constructing normalized growth standards.

Authors:  T J Cole
Journal:  Eur J Clin Nutr       Date:  1990-01       Impact factor: 4.016

10.  Ambulatory blood pressure in type I diabetes mellitus. Comparison to presence of incipient nephropathy in adolescents and young adults.

Authors:  W V Moore; D L Donaldson; A M Chonko; P Ideus; T B Wiegmann
Journal:  Diabetes       Date:  1992-09       Impact factor: 9.461

View more
  22 in total

Review 1.  Microvascular disease in children and adolescents with type 1 diabetes and obesity.

Authors:  M Loredana Marcovecchio; Francesco Chiarelli
Journal:  Pediatr Nephrol       Date:  2010-08-19       Impact factor: 3.714

2.  Transition from pediatric to adult care. eight years after the transition from pediatric to adult diabetes care: metabolic control, complications and associated diseases.

Authors:  Alessandra Rollo; S Salardi; A Ciavarella; G Forlani; M Scipione; G Maltoni; C Balsamo; A L Martini; S Zucchini
Journal:  J Endocrinol Invest       Date:  2014-05-23       Impact factor: 4.256

Review 3.  When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes.

Authors:  Kevin V Lemley
Journal:  Pediatr Nephrol       Date:  2010-03-30       Impact factor: 3.714

Review 4.  Blood pressure variability, cardiovascular risk, and risk for renal disease progression.

Authors:  Gianfranco Parati; Juan E Ochoa; Grzegorz Bilo
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

5.  Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes.

Authors:  Niina Sandholm; Carol Forsblom; Ville-Petteri Mäkinen; Amy Jayne McKnight; Anne-May Osterholm; Bing He; Valma Harjutsalo; Raija Lithovius; Daniel Gordin; Maija Parkkonen; Markku Saraheimo; Lena M Thorn; Nina Tolonen; Johan Wadén; Jaakko Tuomilehto; Maria Lajer; Emma Ahlqvist; Anna Möllsten; M Loredana Marcovecchio; Jason Cooper; David Dunger; Andrew D Paterson; Gianpaolo Zerbini; Leif Groop; Lise Tarnow; Alexander P Maxwell; Karl Tryggvason; Per-Henrik Groop
Journal:  Diabetologia       Date:  2014-03-05       Impact factor: 10.122

6.  High frequency of nocturnal hypertension in lupus nephritis: should ABPM be implemented in usual practice?

Authors:  Juan M Mejia-Vilet; Yesser J López-Hernández; Mariedel Trujeque-Matos; J Iván Santander-Velez; Mayra L Cano-Verduzco; Cristino Cruz; Luis E Morales-Buenrostro
Journal:  Clin Rheumatol       Date:  2019-12-14       Impact factor: 2.980

Review 7.  The renal resistive index as a new complementary tool to predict microvascular diabetic complications in children and adolescents: a groundbreaking finding.

Authors:  Abeer Ahmed Abdel Maksoud; Sherine Mohamed Sharara; Amit Nanda; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2019-09

Review 8.  Blood Pressure Variability and Autonomic Dysfunction.

Authors:  Vincenza Spallone
Journal:  Curr Diab Rep       Date:  2018-10-25       Impact factor: 4.810

9.  Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).

Authors: 
Journal:  BMC Pediatr       Date:  2009-12-17       Impact factor: 2.125

10.  Maternal but not paternal association of ambulatory blood pressure with albumin excretion in young offspring with type 1 diabetes.

Authors:  M Loredana Marcovecchio; Paivi H Tossavainen; Carlo L Acerini; Timothy G Barrett; Julie Edge; Andrew Neil; Julian Shield; Barry Widmer; R Neil Dalton; David B Dunger
Journal:  Diabetes Care       Date:  2009-11-16       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.